OptiBiotix Health PLC Exercise of Options & Director's Dealing (2070D)
October 08 2018 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 2070D
OptiBiotix Health PLC
08 October 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Exercise of Options, Director's Dealing and Issue of Equity
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, received notification on Friday 5 October 2018 for
the exercise of options over 357,722 ordinary shares in the Company
at an exercise price of 20p per share providing the Company with
proceeds of GBP71,554.
The option holder, Dr Gareth Barker, a Non-executive Director of
the Company, has undertaken not to dispose of the 357,722 ordinary
shares for twelve months. Dr Barker has further agreed that he will
only dispose of shares through the Company's broker. After the
twelve month period, the undertaking will no longer be in
place.
Application will be made to the London Stock Exchange to admit
the 357,722 new ordinary shares to trading on AIM. Admission of the
new ordinary shares is expected to occur on or around 11 October
2018. The new ordinary shares will rank pari passu with the
existing ordinary shares.
For the purpose of the Disclosure and Transparency Rules,
following the issue of shares detailed above the enlarged issued
share capital of the Company will comprise 84,724,363 ordinary
shares of 2p each. There are no ordinary shares held in treasury.
The above figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in, the
Company, under the Disclosure and Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 and the person who arranged
for release of this announcement on behalf of the Company was Mark
Collingbourne, Chief Financial Officer.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Cairn Financial Advisers LLP Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Abigail Wayne (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
-------------------------------------------------------------------------------------------------
a. Name Dr Gareth Barker
--------------------------------------- --------------------------------------------------------
2 Reason for notification
--------------------------------------- --------------------------------------------------------
a. Position/Status Non-executive Director of the Company
--------------------------------------- --------------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
--------------------------------------- --------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------------------------
a. Name OptiBiotix Health Plc
--------------------------------------- --------------------------------------------------------
b. LEI 213800UKYQFT941QHS14
--------------------------------------- --------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-------------------------------------------------------------------------------------------------
a. Description of
the financial Options over 357,722 ordinary shares of
instrument, type 2p each
of instrument
Identification
Code ISIN: GB00BP0RTP38
--------------------------------------- --------------------------------------------------------
b. Nature of the Exercise of options to purchase ordinary
transaction shares of the Company. Following the transaction,
Dr Gareth Barker has an interest in 357,722
ordinary shares.
--------------------------------------- --------------------------------------------------------
c. Price(s) and volume(s) Price(s) per Volume(s)
share
--------------------------------------- ------------------------------
20p 357,722
------------------------------ ---------------------
Aggregated information
- Aggregated Volume 357,722
d. - Price 20p
--------------------------------------- --------------------------------------------------------
e. Date of the transaction 5 October 2018
--------------------------------------- --------------------------------------------------------
f. Place of the transaction London Stock Exchange, AIM
--------------------------------------- --------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCMMMGGZNFGRZZ
(END) Dow Jones Newswires
October 08, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024